Journal of Nuclear Medicine

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Csh, Endocrine, Proquest, Ama, Nephrology, Highwire from 1964, Aaas, Rupress, CSA, and Aacr

  1. Discriminating ability of (18)F-FET PET for several cerebral neoplastic lesions.

    Journal of Nuclear Medicine 55(1):176 (2014) PMID 24198384

  2. Reply: cadmium-zinc-telluride SPECT in very morbidly obese patients routinely provides high-diagnostic-quality myocardial perfusion imaging.

    Journal of Nuclear Medicine 54(4):661 (2013) PMID 23667920

  3. 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment.

    Journal of Nuclear Medicine 50(9):1455 (2009) PMID 19690024

    Postmortem binding studies have established that the concentration of alpha(4)beta(2)-nicotinic acetylcholine receptors (alpha(4)beta(2)-nAChR) is reduced in advanced Alzheimer disease (AD). However, the status of this receptor in mild or prodromal AD has remained the subject of controversy. We ...
  4. Hypertension increases cerebral 6-18F-fluorodopa-derived radioactivity.

    Journal of Nuclear Medicine 50(9):1479 (2009) PMID 19690020 PMCID PMC4164388

    6-(18)F-fluorodopa PET depicts the striatal dopaminergic lesion characterizing Parkinson disease (PD); however, striatal uptake of 6-(18)F-fluorodopa-derived radioactivity can be normal. Supine hypertension (SH) might increase 6-(18)F-fluorodopa uptake. We measured putamen, caudate, and occipita...
  5. In vivo characterization of a series of 18F-diaryl sulfides (18F-2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)phenylthio)benzenamine) for PET imaging of the serotonin transporter.

    Journal of Nuclear Medicine 50(9):1509 (2009) PMID 19690040

    PET of the serotonin transporter (SERT) in the brain is a useful tool for examining normal physiologic functions as well as disease states involving the serotonergic system. The goal of this study was to further develop and refine a series of 4'-fluoroalkoxy-substituted, (18)F-radiolabeled SERT ...
  6. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.

    Journal of Nuclear Medicine 50(9):1533 (2009) PMID 19690032

    Assessment of osteosarcoma response to neoadjuvant chemotherapy is performed by histopathologic analysis after surgical resection of the primary tumor. The purpose of this study was to evaluate whether (18)F-FDG PET could be a noninvasive surrogate to histopathologic analysis and allow for earli...
  7. Molecular imaging of cartilage.

    Journal of Nuclear Medicine 50(9):1391 (2009) PMID 19690037

  8. Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines.

    Journal of Nuclear Medicine 50(9):1525 (2009) PMID 19690031

    The (18)F-FDG uptake pattern on PET could be an indicator of the prognosis and aggressiveness of various tumors, including hepatocellular carcinoma (HCC). Hexokinase, especially hexokinase type II (HKII), plays a critical role in (18)F-FDG uptake in rapidly growing tumors. We established a stabl...
  9. Combination of converging collimators for high-sensitivity brain SPECT.

    Journal of Nuclear Medicine 50(9):1548 (2009) PMID 19690042

    The objective of this study, which is related to human brain SPECT, was to increase the sensitivity of a triple-camera SPECT system and reduce statistical noise in reconstructed images using a combination of converging collimators. The reason for combining collimators is to ensure both high sens...
  10. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.

    Journal of Nuclear Medicine 50(9):1394 (2009) PMID 19690023

    The purpose of this study was to investigate the effect of total prostate-specific antigen (PSA) at the time of (11)C-choline PET/CT (trigger PSA), PSA velocity (PSAvel), and PSA doubling time (PSAdt) on (11)C-choline PET/CT detection rate in patients treated with radical prostatectomy for prost...
  11. First preclinical imaging of primary cartilage neoplasm and its local recurrence using 99mTc-NTP 15-5 radiotracer.

    Journal of Nuclear Medicine 50(9):1541 (2009) PMID 19690026

    This study on a rat model of grade II chondrosarcoma aimed to determine whether the radiotracer N-(triethylammonium)-3-propyl-[15]ane-N5 radiolabeled with (99m)Tc ((99m)Tc-NTP 15-5), which binds to cartilage proteoglycans, has pathophysiologic validity for in vivo imaging of cartilage tumoral ti...
  12. Directions and magnitudes of misregistration of CT attenuation-corrected myocardial perfusion studies: incidence, impact on image quality, and guidance for reregistration.

    Journal of Nuclear Medicine 50(9):1471 (2009) PMID 19690038

    CT-based attenuation-corrected (AC) myocardial perfusion imaging (MPI) studies may show significant artifacts caused by misregistration between SPECT and CT data. The present study aimed at identifying the directions and magnitudes of misregistration with greatest impact on AC myocardial perfusi...
  13. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.

    Journal of Nuclear Medicine 50(9):1435 (2009) PMID 19690035

    Response to neoadjuvant chemotherapy is a significant prognostic factor for osteosarcoma; however, this information can be determined only after surgical resection. If we could predict histologic response before surgery, it might be helpful for the planning of surgeries and tailoring of treatmen...
  14. Dosimetry of Pediatric PET/CT.

    Journal of Nuclear Medicine 50(9):1483 (2009) PMID 19690036

    The use of PET/CT in children has grown substantially in the past few years. There is also an increased interest in keeping the radiation dose to children from CT as low as is clinically practical. This article reviews the physical aspects of both PET and CT separately and how CT is used in the ...
  15. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.

    Journal of Nuclear Medicine 50(9):1427 (2009) PMID 19690033

    (68)Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide (DOTA-TOC) PET has proven its usefulness in the diagnosis of patients with neuroendocrine tumors. Radionuclide therapy ((90)Y-DOTA-TOC or (177)Lu-DOTA-octreotate) is a choice of treatment that...
  16. Initial characterization of a dedicated breast PET/CT scanner during human imaging.

    Journal of Nuclear Medicine 50(9):1401 (2009) PMID 19690029 PMCID PMC2872060

    We have constructed a dedicated breast PET/CT scanner capable of high-resolution functional and anatomic imaging. Here, we present an initial characterization of scanner performance during patient imaging. The system consisted of a lutetium oxyorthosilicate-based dual-planar head PET camera (cry...
  17. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.

    Journal of Nuclear Medicine 50(9):1441 (2009) PMID 19690030

    We determined the ability of PET with the thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) to detect hepatocellular carcinoma (HCC). In this pilot study, (18)F-FLT PET was performed in 18 untreated patients with clinically suspected HCC. Routine diagnostic procedures included ultra...
  18. New agents and techniques for imaging prostate cancer.

    Journal of Nuclear Medicine 50(9):1387 (2009) PMID 19690043 PMCID PMC3336101

    The successful management of prostate cancer requires early detection, appropriate risk assessment, and optimum treatment. An unmet goal of prostate cancer imaging is to differentiate indolent from aggressive tumors, as treatment may vary for different grades of the disease. Different modalities...
  19. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.

    Journal of Nuclear Medicine 50(9):1448 (2009) PMID 19690028 PMCID PMC4722807

    Although (123)I-MIBG has been in clinical use for the imaging of pheochromocytoma for many years, a large multicenter evaluation of this agent has never been performed. The present study was designed to provide a prospective confirmation of the performance of (123)I-MIBG scintigraphy for the eva...
  20. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression.

    Journal of Nuclear Medicine 50(9):1492 (2009) PMID 19690041 PMCID PMC4216181

    Affibody molecules are a class of scaffold proteins being developed into a generalizable approach to targeting tumors. Many 3-helix-based Affibody proteins have shown excellent in vivo properties for tumor imaging and therapy. By truncating one alpha-helix that is not responsible for receptor re...